ArriVent BioPharma, Inc. Common StockAVBPNASDAQ

Revenue (LTM)

Net Income (LTM)

$-166M

-106.6% YoY

Free Cash Flow

$-161M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	0	0
Gross Profit	0	0	0	0	0
Operating Income	-9	-37↓324.4%	-75↓102.1%	-94↓26.4%	-178↓88.2%
Net Income	-52	-37↑28.5%	-69↓87.9%	-80↓16.1%	-166↓106.6%
EBITDA	-52	0	-75	-80↓7.9%	-178↓120.6%
EPS Diluted	-40.44	-1.10↑97.3%	-2.17↓97.3%	-2.56↓18.0%	-4.32↓68.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	37	163↑338.2%	150↓7.9%	74↓50.6%	46↓38.7%
Total Current Assets	43	183↑325.2%	160↓12.4%	227↑41.9%	333↑46.7%
Total Assets	43	183↑324.8%	163↓10.8%	275↑68.6%	333↑21.2%
Total Current Liabilities	2	8↑359.8%	12↑39.0%	17↑48.6%	26↑50.2%
Total Liabilities	2	8↑360.5%	12↑41.0%	17↑46.5%	26↑50.1%
Total Equity	41	174↑323.2%	151↓13.3%	258↑70.3%	307↑19.2%
Total Debt	0	0	0↑128.1%	0↓44.5%	0↓92.0%
Net Debt	-37	-163↓337.9%	-150↑8.1%	-74↑50.6%	-46↑38.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-13	-44↓246.6%	-56↓28.0%	-70↓25.7%	-161↓128.7%
Capital Expenditure	0	0	0	0	0
Free Cash Flow	-13	-44↓246.6%	-56↓28.0%	-70↓25.7%	-161↓128.7%
Stock-Based Comp	0	0	1↑111.1%	3↑258.4%	13↑290.3%
Net Change in Cash	37	126↑238.2%	-13↓110.3%	-76↓486.1%	-29↑62.2%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance